1. Introduction {#sec0005}
===============

Curative resection is an important prognostic factor in intrahepatic cholangiocarcinoma (ICC); however, certain segments remain unresectable. Recently, the efficacy of combined therapy with systemic chemotherapy, interventional therapy, and hepatic curative resection for very advanced inoperable ICCs have been reported \[[@bib0005], [@bib0010], [@bib0015], [@bib0020]\]. This paper reports the feasibility of multimodal chemotherapy including hepatic arterial chemoembolization with drug-eluting beads (DEB-TACE), angiographic subsegmentectomy (AS), systemic chemotherapy following radical surgery. This case report was in accordance with the SCARE criteria \[[@bib0025]\].

2. Case report {#sec0010}
==============

Here, we reported ICC in a 59-year-old Japanese woman with back pain, who had been referred to our hospital by her family physician. There were no special notes in her past medical, drug, and family history, or in her relevant physical examination and other significant clinical findings including no alcoholic habits. At admission, the CEA and CA19-9 levels were 910.5 ng/mL and 1965.3 U/mL, respectively. There were no evidences of hepatitis infection. ([Table 1](#tbl0005){ref-type="table"}). Computed tomography (CT) findings revealed the presence of two low-density masses 68 mm in diameter in hepatic segments 2 and 3 and 72 mm in diameter in segment 8, with early enhancement of the peripheral area as the main loci. Magnetic resonance cholangiopancreatography revealed dilation of the distal intrahepatic bile duct from the tumors. Radiological findings as irregular masses of relatively low attenuation in the early phase that demonstrate minimal contrast enhancement at the periphery with focal intrahepatic bile duct dilatation showed peripheral cholangiocarcinoma. These tumors were clinically diagnosed as ICC and were suspected to invade the right Glisson's sheath with multiple intrahepatic metastases classed as stage ⅣA according to the TMN classification, and were deemed initially unresectable ([Fig. 1](#fig0005){ref-type="fig"}, [Fig. 2](#fig0010){ref-type="fig"}). After hepatic arterial chemoembolization therapy with drug-eluting beads (DEB-TACE), angiographic-subsegmentectomy (AS) and systemic chemotherapy with Gemcitabine and S1 were performed, tumor shrinkage was confirmed, and the tumor markers decreased to just above the normal range ([Fig. 3](#fig0015){ref-type="fig"}). Thus, the patient was referred to our hospital for surgery. CT revealed that the tumor did not invade the right Glisson's sheath and the intrahepatic metastases disappeared ([Fig. 4](#fig0020){ref-type="fig"}). After the simulation of hepatic resection, left lateral segmentectomy and 8th subsegmentectomy were performed ([Fig. 5](#fig0025){ref-type="fig"}). Blood loss was 600 mL, and the operative time was 470 min. Pathological examination after R0 resection revealed that no viable neoplastic cells remained in the specimen ([Fig. 6](#fig0030){ref-type="fig"}). The patient was discharged on day 29 after surgery without complications, and no chemotherapy was administered. Two years and 10 months after the surgery, the patient is alive without relapse ([Fig. 7](#fig0035){ref-type="fig"}).Table 1Laboratory test results.Table 1WBC930010 ^4^/μlPT(%)96.1%RBC41510 ^4^/μlPT(INR)1.02Hb12.2g/dlAPTT29.8secHt37.3%Plt27.310 [@bib0020]/μlICGR156.8%CRP0.77mg/dlAlb4.3g/dlCEA910.5ng/mlT-bil0.71mg/dlCA19-91965.3U/mlALT25IU/lAFP5ng/mlAST31IU/lPIVKAⅡ13mAU/mlALP206IU/lɤ-GTP101IU/lBUN10.7mg/dlHCV Ab(-)Cre0.67mg/dlHBV Ab(-)Na141mEq/lHBV Ag(-)K4.2mEq/lCl103mEq/lFig. 1CT images at admission.Computed tomography (CT) showed two low-density masses of 68 mm in diameter in hepatic segments 2 and 3 and 72 mm in diameter in segment 8 as the main loci. These tumors were diagnosed as intrahepatic cholangiocarcinoma and were suspected to invade the right Glisson's sheath (blue triangle) with multiple intrahepatic metastases (red triangles).Fig. 1Fig. 2MRI images at admission.Peripheral dilation of the intrahepatic bile duct of the 8th branch can be seen, suggesting bile duct invasion.Fig. 2Fig. 3Changes in tumor markers following multimodal therapy.After two rounds of DEB-TACE with epirubicin and AS, tumor markers decreased to 20% of the initial level. After the systemic chemotherapy with gemcitabine and S1, the tumor markers decreased to just above the normal range.Fig. 3Fig. 4CT images after multimodal therapy.CT images revealed tumor shrinkage and disappearance of the invasion to the right Glisson's sheath and of the intrahepatic metastases.Fig. 4Fig. 5Operation images.The image illustrates a left lateral segmentectomy and 8th subsegmentectomy.Fig. 5Fig. 6Pathological examination.No viable neoplastic cells were present in the specimen.Fig. 6Fig. 7Postsurgical changes in the levels of tumor markers.Tumor marker levels decreased to within the normal range after surgery.Fig. 7

3. Discussion {#sec0015}
=============

Curative R0 resection resulted in improved survival and has been reported to be an extremely important prognostic variable of ICC \[[@bib0030],[@bib0035]\]. However, a portion of the ICC that had been diagnosed as unresectable at admission remained. In ICC, larger tumor size, multifocal disease, lymph node metastasis, and vascular invasion were considered as poor prognostic factors for survival \[[@bib0040]\]. In this case, MRI scans at admission revealed intrahepatic multifocal disease and vascular invasion. Thus, the surgical approach was not indicated.

Recently, chemotherapy and/or interventional approach, i.e., hepatic angiographic infusion of anticancer agents, transarterial chemoembolization (TACE), and transarterial radioembolization, revealed prolongation of survival \[[@bib0005], [@bib0010], [@bib0015], [@bib0020], [@bib0025]\]. According to the reported clinical outcomes of doxorubicin treatment for unresectable ICC, the ratio of partial response and stable disease was 15% and 80%, respectively. Furthermore, the availability of DEB-TACE has been mentioned in particular \[[@bib0045]\]. In this case report, DEB-TACE was introduced two times with epirubicin and AS. AS was associated with a high disease-free survival rate for hepatocellular carcinoma as hepatectomy \[[@bib0050]\]. In the present case, tumor size was reduced and tumor markers were decreased to 20% of the levels at admission.

The overall survival in the combined therapy of hepatic arterial infusion and systemic chemotherapy was longer than that in patients who received systemic chemotherapy alone \[[@bib0055]\]. Thus, systemic chemotherapy with gemcitabine and S1 was introduced. However, tumor markers did not decrease to within the normal range. Consequently, it was assumed that viable tumor cells remained. The patient was referred to our hospital for surgical indication of hepatectomy to reevaluate the possibility of R0 resection.

[Table 2](#tbl0010){ref-type="table"} shows the successful radical resection of the initially unresectable ICC \[[@bib0005],[@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085], [@bib0090], [@bib0095]\]. In previous reports ([Table 2](#tbl0010){ref-type="table"}), several effective anticancer agents for ICC were administered: mitomycin C, epirubicin; gemcitabine; cisplatin; 5-furuolouracil, capecitabine, and S1. Epirubicin, gemcitabine, and S1 were selected for the present case. The successful downstaging and R0 resection rate increased from 7.7% to 36.4% using anticancer drugs, and the rate elevated from 17.7% up to 73.3% with radiation. In some reports, the morbidity rate was reported to be 25%. Although transplants had a higher R0 resection rate of 80% and a higher overall survival rate of 75%, the mortality rate was 12.5% (1/8 patients). Pathological examination revealed no residual malignant cells after multimodal therapy in our case. To our knowledge, a pathological complete remission rate of 38% is the highest level in the chemoradiation series. Neoadjuvant therapy for initially unresectable ICC aims to reduce tumor size and to prolong survival, and to get chances of conversion for surgical resection. Conversion rate was reported up to 12.5% in the series of DEB-TACE \[[@bib0100]\]. Our strategy for unresctable ICC was intrahepatic arterial chemo-embolization with DEB-TACE initially. This combination therapy with interventional approach and systemic chemotherapy followed by radical surgical resection has potential as an effective approach for initially unresectable and locally advanced ICC.Table 2Results of neoadjuvant therapy following radical surgery for initially unresectable ICC.Table 2authoryearNumber^(\*)^age median(min-max)chemotherapyRouteradiationradiation dose (method)ProcedureOperated numberresection rate (%)R numbernumberMST(M)RecCommentsWu20071ICC75MMC + EpirubicinTACE(−)Hepatectomy1(−)R0R0:1420Kato A20127ICC67 (57--84)GEMi.v.(−)Hepatectomy436.4R0R0:428.50Aoki Y20141ICC83GEM + CDDPi.v.(−)Hepatectomy1(−)R0R0:180Rayar M201545ICC68 (39--79)GEM, 5-FU, OXP, CDDPTAR(+)(yttrium-90)Hepatectomy817.8R0R0:817.82morbidity 25%Marchan EM201510CCA58.3 (38--71)XEL or 5-FUp.o. or i.v.(+)59 Gy (Ir brachytherapy HDR/external boost)Transplantation880R0R0:80pCR 38%Konstantinidis IT2016104ICC62 (30--88)FUDR, MMC, GEMHAI and/or SYS(−)Hepatectomy87.7R0R0:236.96morbidity 25% (2:perooperative death)Takayamagi R20171ICC23GEM + CDDPi.v.(−)Hepatectomy1(−)R0R0:1311CRSumiyoshi T20187(15)ICC70 (60--78)S1 or CDDP + CPT11p.o. or i.v.(+)50GyHepatectomy571.4R0R0:4183PR(4), SD(1)Sugiyama K20181ICC635-FU + CDDPTAC(+)40GyHepatectomy1(−)R1R1:1170[^1]
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[^1]: Number(\*): Entered as ICC or CCA, ICC: Intrahepatic cholangiocarcinoma, CCA: Cholangiocellar carcinoma, MMC: Mitomycin C, GEM: Gemcitabine, CDDP: Cisplatin, OXP: Oxaliplatin, XEL: Capecitabine, 5-FU: 5-Furuolouracil, FUDR: Doxifluridine, S1: Tegafur/Gimeracil/Oteracil, CPT-11: Irinotecan, Ir: Iridium192, HDR: high dose rate, TACE: Transcatheter Arterial Chemo-Embolization, i.v.: Intravenous, TAR: Transarterial radiation, p.o.: per os, HAI: Hepatic arterial infusion, SYS: Systemic chemotherapy, TAC: Transarterial chemotherapy, R0: cor-responds to complete disease remission, R1: clinical complete disease remission, but with unexpected identiﬁcation of a tumor, MST: Median survival time, Rec: Recurrence, CR: Complete remission, PR: Partial response, SD: Staple disease.
